Bharat Biotech joins GSK to develop a Shigella vaccine to fight shigellosis in children, with Phase 3 trials underway and ...

After nearly 25 years with Sanofi, Sanjay Gurunathan, M.D., has left for GSK, where he will lead vaccine and infectious ...

Dow Jones Newswires is a market-moving financial and business news source, used by wealth managers, institutional investors and fintech platforms around the world to identify trading and investing ...

Bharat Biotech to advance development of GSK's Shigella vaccine candidate for severe bacterial diarrhoea: Our Bureau, Bengaluru Thursday, June 12, 2025, 15:30 Hrs [IST] Bharat Bio ...

The release of Pretty Hurts comes two years after GSK collaborated with Lifetime on a short film highlighting the risks ...

GSK PLC GSK shares rallied 1.20% to £15.12 Thursday, on what proved to be an all-around favorable trading session for the ...

The trial evaluated the combination of GSK’s Jemperli and Zejula as a first-line therapy for stage III and IV epithelial OC.

With that, Theravance expects its lifetime value from the inhaler to come out to $1.52 billion. The drug stems from a 2002 ...

S hares of global vaccine makers were muted on Tuesday as investors and analysts took a "wait and watch" approach after U.S.

UK pharma major GSK has appointed Sanjay Gurunathan as senior vice president and global head vaccines and infectious disease ...

Both companies viewed the early end to the PIVOT-PO trial as a positive development, with GSK saying it would work with US ...

The GSK share price has had a horrible millennium. Harvey Jones can't believe how bad it's been. But are we starting to see ...